Biocept (FRA:B00) Debt-to-Equity : 39.92 (As of Jun. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Biocept Debt-to-Equity?

Biocept's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was €1.76 Mil. Biocept's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was €8.94 Mil. Biocept's Total Stockholders Equity for the quarter that ended in Jun. 2023 was €0.27 Mil. Biocept's debt to equity for the quarter that ended in Jun. 2023 was 39.92.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Biocept's Debt-to-Equity or its related term are showing as below:

FRA:B00' s Debt-to-Equity Range Over the Past 10 Years
Min: -21.97 Med: 0.36 Max: 39.97
Current: 39.97

During the past 12 years, the highest Debt-to-Equity Ratio of Biocept was 39.97. The lowest was -21.97. And the median was 0.36.

FRA:B00's Debt-to-Equity is ranked worse than
100% of 195 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.22 vs FRA:B00: 39.97

Biocept Debt-to-Equity Historical Data

The historical data trend for Biocept's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocept Debt-to-Equity Chart

Biocept Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

Get a 7-Day Free Trial

0.54

0.23

0.52

0.34

1.37

Biocept Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Debt-to-Equity	Get a 7-Day Free Trial															0.38	0.45	1.37	4.77	39.92

Competitive Comparison of Biocept's Debt-to-Equity

For the Diagnostics & Research subindustry, Biocept's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biocept's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Biocept's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Biocept's Debt-to-Equity falls into.

Biocept Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Biocept's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.637	+	9.794)	/	8.364
	=	1.37

Biocept's Debt to Equity Ratio for the quarter that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.759	+	8.939)	/	0.268
	=	39.92

Biocept (FRA:B00) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Biocept Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Biocept's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Biocept (FRA:B00) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biocept Inc (FRA:B00) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

BIOCQ:USA

Address

9955 Mesa Rim Road, San Diego, CA, USA, 92121

Website

https://www.biocept.com

Biocept Inc develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept's patented Target Selector technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. It is also leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.

Biocept (FRA:B00) Headlines

No Headlines